dpp 4 inhibitor and glp 1 agonist Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1 GLP-1-based therapies, including GLP-1, GLP-1R

[PMC free article] [PubMed] [Google Scholar] 50

The Stanford Medicine clinicians we spoke with pushed back on that framing

Zeitschrift fr physiologische Chemie (in German)

References Lau, D., Erichsen, L., Francisco, A., Satylganova, A., Roux, C., McGowan, B., Pedersen, S., Pietilinen, K., Rubino, D., & Batterham, R

GLP-1RA Liraglutide Semaglutide Efpeglenatide Glucose lowering effect CV system protection effect Kidney protection effect Nonalcoholic fatty liver disease GIP/GLP1 receptor coagonists: tirzepatide Amylin/GLP1 receptor coagonists: CagriSema (cagrilintide+semaglutide) Glucagon/GLP1 receptor coagonists: survodutide GIP/GLP1/glucagon receptor triple coagonists: retatrutide Obesity is a disease that can be treated with targeted pharmacotherapy in addition to lifestyle modification and behavioral interventions